{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:34:51Z","timestamp":1761896091740,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,7,5]],"date-time":"2015-07-05T00:00:00Z","timestamp":1436054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board (IN)","doi-asserted-by":"publisher","award":["SERB- SB\/FT\/LS-147\/2012"],"award-info":[{"award-number":["SERB- SB\/FT\/LS-147\/2012"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s12032-015-0665-0","type":"journal-article","created":{"date-parts":[[2015,7,4]],"date-time":"2015-07-04T07:54:52Z","timestamp":1435996492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1\u00a0year in chronic myeloid leukemia patients treated with imatinib"],"prefix":"10.1007","volume":"32","author":[{"given":"Jose","family":"Francis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh Chandra","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adithan","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,5]]},"reference":[{"key":"665_CR1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031\u20137.","journal-title":"N Engl J Med"},{"key":"665_CR2","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3109\/10428194.2012.694076","volume":"53","author":"KC Lakshmaiah","year":"2012","unstructured":"Lakshmaiah KC, Bhise R, Purohit S, et al. Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. Leuk Lymphoma. 2012;53:2430\u20133.","journal-title":"Leuk Lymphoma"},{"key":"665_CR3","doi-asserted-by":"crossref","unstructured":"Deininger M, O\u2019Brien S, Guilhot F, et al. International randomized study of interferon and STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood. 2009;114:Abstract 1126.","DOI":"10.1182\/blood.V114.22.1126.1126"},{"issue":"21","key":"665_CR4","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F, et al. Gruppo Italiano Malattie Ematologiche dell\u2019Adulto CML Working Party. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML working party. Blood. 2011;117(21):5591\u20139.","journal-title":"Blood"},{"key":"665_CR5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood. 1984;63:789\u201399.","journal-title":"Blood"},{"key":"665_CR6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing committee for the collaborative CML prognostic factors project group. J Natl Cancer Inst. 1998;90:850\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"665_CR7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686\u201392.","journal-title":"Blood"},{"key":"665_CR8","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2011.37.6962","volume":"29","author":"D Marin","year":"2011","unstructured":"Marin D, Ibrahim AR, Goldman JM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol. 2011;29:3944\u20135.","journal-title":"J Clin Oncol"},{"key":"665_CR9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1179\/1607845412Y.0000000071","volume":"18","author":"B Uz","year":"2013","unstructured":"Uz B, Buyukasik Y, Atay H, et al. EUTOS CML prognostic scoring system predicts ELN-based \u2018event-free survival\u2019 better than Euro\/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology. 2013;18:247\u201352.","journal-title":"Hematology"},{"key":"665_CR10","doi-asserted-by":"crossref","unstructured":"Yahng SA, Jang EJ, Choi SY, et al. Comparison of Sokal, Hasford and EUTOS scores in terms of long-term treatment outcome according to the risks in each prognostic model: a single center data analyzed in 255 early chronic phase chronic myeloid leukemia patients treated with frontline imatinib mesylate. Blood. 2012;120:Abstract 2794.","DOI":"10.1182\/blood.V120.21.2794.2794"},{"key":"665_CR11","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496\u20139.","journal-title":"Blood"},{"key":"665_CR12","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022\u20138.","journal-title":"Blood"},{"key":"665_CR13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/FTD.0000000000000013","volume":"36","author":"S Francia De","year":"2014","unstructured":"De Francia S, D\u02bcAvolio A, Ariaudo A, Pirro E, Piccione F, Simiele M, Fava C, Calcagno A, Di Perri G, Saglio G. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia. Ther Drug Monit. 2014;36:410\u20132.","journal-title":"Ther Drug Monit"},{"key":"665_CR14","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.leukres.2014.03.023","volume":"38","author":"V Gotta","year":"2014","unstructured":"Gotta V, Bouchet S, Widmer N, Schuld P, Decosterd LA, Buclin T, Mahon FX, Csajka C, Molimard M. Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. Leuk Res. 2014;38:764\u201372.","journal-title":"Leuk Res"},{"key":"665_CR15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","volume":"17","author":"K Eechoute","year":"2011","unstructured":"Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, Loos WJ, Wiemer EA, Mathijssen RH. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res. 2011;17:406\u201315.","journal-title":"Clin Cancer Res"},{"key":"665_CR16","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.4161\/cc.3.12.1331","volume":"3","author":"H Burger","year":"2004","unstructured":"Burger H, Nooter K. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle. 2004;3:1502\u20135.","journal-title":"Cell Cycle"},{"key":"665_CR17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","volume":"55","author":"N Takahashi","year":"2010","unstructured":"Takahashi N, Miura M, Scott SA. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet. 2010;55:731\u20137.","journal-title":"J Hum Genet"},{"key":"665_CR18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","volume":"8","author":"ER Gardner","year":"2006","unstructured":"Gardner ER, Burger H, van Schaik RH, et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther. 2006;8:192\u2013201.","journal-title":"Clin Pharmacol Ther"},{"issue":"122","key":"665_CR19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"8","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;8(122):872\u201384.","journal-title":"Blood"},{"key":"665_CR20","first-page":"1067","volume":"3","author":"J Francis","year":"2014","unstructured":"Francis J, Dubashi B, Sundaram R, et al. A simple and rapid method for the quantification of Imatinib mesylate and desmethyl imatinib in human Plasma using lc-ms\/ms and its application to routine therapeutic drug monitoring. World J Pharma Res. 2014;3:1067\u201375.","journal-title":"World J Pharma Res"},{"key":"665_CR21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12185-014-1600-4","volume":"100","author":"SA Yahng","year":"2014","unstructured":"Yahng SA, Jang EJ, Choi SY, et al. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population. Int J Hematol. 2014;100:132\u201340.","journal-title":"Int J Hematol"},{"issue":"14","key":"665_CR22","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","volume":"1","author":"A Petain","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res. 2008;1(14):7102\u20139.","journal-title":"Clin Cancer Res"},{"issue":"112","key":"665_CR23","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","volume":"1","author":"S Dulucq","year":"2008","unstructured":"Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008;1(112):2024\u20137.","journal-title":"Blood"},{"issue":"15","key":"665_CR24","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DH Kim","year":"2009","unstructured":"Kim DH, Sriharsha L, Xu W, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009;15(15):4750\u20138.","journal-title":"Clin Cancer Res"},{"key":"665_CR25","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00280-014-2599-1","volume":"74","author":"V Gotta","year":"2014","unstructured":"Gotta V, Widmer N, Decosterd LA, et al. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chemother Pharmacol. 2014;74:1307\u201319.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0665-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-015-0665-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0665-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T15:23:00Z","timestamp":1599232980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-015-0665-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,5]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1007\/s12032-015-0665-0","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2015,7,5]]},"article-number":"213"}}